LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab, a chimeric monoclonal IgG1 antibody that selectively binds to TNF-α. It is used for the quantitative assessment of Infliximab.

Anti-TNF antibodies, which block TNF alpha action, have transformed the treatment of TNF-related diseases, including Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. By neutralizing TNF activity, these antibodies not only facilitate mucosal healing but also induce long-term remissions in vivo. The primary anti-TNF antibodies approved for use are Infliximab, Etanercept, Adalimumab, Certolizumab, and Golimumab[1].